Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability and PK of JNJ-39393406 in Healthy Subjects
NCT02023255Phase 1Completed
- Sponsor
- Johnson & Johnson
- Start
- Jan 2009
- Primary completion
- Jun 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of JNJ-39393406 in schizophrenia, Alzheimer's disease (AD), major depressive disorder (MDD) and 1 more (8 cohorts), sponsored by Johnson & Johnson. Primary endpoints: Number of participants with adverse events, Maximum Observed Plasma Concentration at Day 14 and 6 more. Started Jan 2009; status: completed.
02
Drugs
JNJ-39393406
03
Conditions
schizophreniaAlzheimer's disease (AD)major depressive disorder (MDD)Tobacco Use Disorder (TUD)
Beyond the preview
Go deeper on NCT02023255.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02023255.